

Dated: August 27, 1999.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-22866 Filed 9-1-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Availability of Draft Guidelines for Prevention of Opportunistic Infections in Bone Marrow Transplant Recipients

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

ACTION: Notice of availability and request for comments.

SUMMARY: This notice announces the availability of a draft document entitled "Guidelines for the Prevention of Opportunistic Infections in Bone Marrow Transplant Recipients," prepared by the Centers for Disease Control and Prevention (CDC), for review and comment.

DATES: To ensure consideration, written comments on this draft document must be received on or before November 1, 1999.

ADDRESSES: The draft document "Guidelines for the Prevention of Opportunistic Infections in Bone Marrow Transplant Recipients" can be accessed electronically at <<http://www.cdc.gov/ncidod/dastlr/announce.html>>. Alternatively, single copies of the draft are available by mail from Jackie Curlew, CDC, National Center for Infectious Diseases, Division of AIDS, STD, and TB Laboratory Research, Mailstop A-12, 1600 Clifton Rd., NE, Atlanta, GA 30333, telephone (404) 639-4581, FAX (404) 639-4664. Written comments on the draft document should be sent to the above address for receipt by November 1, 1999.

FOR FURTHER INFORMATION CONTACT: CDC, National Center for Infectious Diseases, Division of AIDS, STD, and TB Laboratory Research, Mailstop A-12, Atlanta, GA 30333; telephone (404) 639-4581, FAX (404) 639-4664.

SUPPLEMENTARY INFORMATION: Opportunistic infections constitute a major cause of morbidity and mortality in bone marrow transplant recipients. These draft guidelines, prepared by CDC, in consultation with representatives from other public and private organizations and bone marrow

transplant centers, represent a comprehensive approach to preventing opportunistic infections (e.g., viral, bacterial, mycotic, and parasitic infections) in bone marrow transplant recipients.

Dated: August 27, 1999.

Joseph R. Carter,

Associate Director for Management and Operations Centers for Disease Control and Prevention.

[FR Doc. 99-22867 Filed 9-1-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Office of AIDS Research Advisory Council.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Office of AIDS Research Advisory Council.

Date: October 14-15, 1999.

Time: October 14, 1999, 8:45 am to 4:30 pm.

Agenda: The role of the Federal Government in AIDS drug discovery, therapeutics, and clinical evaluation.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 6, Bethesda, MD 20892.

Time: October 15, 1999, 8:45 am to 4:30 pm.

Agenda: Continue agenda items from the previous day.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Linda Reck, Head, Program, Planning and Evaluation, Office of AIDS Research, NIH, Bethesda, MD 20892, (301) 402-8655.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds; 93.22, Clinical Research Loan Repayment Program for Individuals with Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program, National Institutes of Health, HHS)

Dated: August 26, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-22827 Filed 9-1-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Biobehavioral Bases of CHD Risk and Management.

Date: September 15, 1999.

Time: 3:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Rockledge Bldg. II, 6701 Rockledge Dr., Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Anthony M. Coelho, Leader, Clinical Studies SRG, NIH, NHLBI, DEA, Review Branch, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892-7924, (301) 435-0288.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Coronary Artery Disease Risk Development in Young Adults Study; Computed Tomography Reading Center.

Date: September 27, 1999.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: 6701 Rockledge Dr., Room 4212, Bethesda, MD 20817, (Telephone Conference Call).

Contact Person: David T. George, Scientific Review Administrator, Review Branch, NIH, NHLBI, DEA, Rockledge II, 6701 Rockledge Drive, Suite 7188, Bethesda, MD 20892-7924, (301) 435-0280.